Impact of Three-dimensional Visualization on Operation Strategy and Complications for Hilar Cholangiocarcinoma

Sponsor
Zhujiang Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT03132649
Collaborator
(none)
300
1
26.5
11.3

Study Details

Study Description

Brief Summary

The aim of the multi-centre study is to evaluate correctly the impact of three-dimensional visualization on operation strategy and complications for hilar cholangiocarcinoma.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Because of the complexity of hilar cholangiocarcinoma,the limitations of 2D images of CT/MRI and the uncertainty of surgeons'experience, it is difficult for the surgeons to diagnosis and assess the operation strategy accurately based on traditional 2D imaging(CT/MRI).The aim of the multi-centre study is to evaluate correctly the impact of three-dimensional visualization on operation strategy and complications for hilar cholangiocarcinoma.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    300 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Impact of Three-dimensional Visualization on Operation Strategy and Complications for Hilar Cholangiocarcinoma
    Actual Study Start Date :
    Mar 15, 2017
    Anticipated Primary Completion Date :
    Jun 1, 2019
    Anticipated Study Completion Date :
    Jun 1, 2019

    Outcome Measures

    Primary Outcome Measures

    1. Impact on operation strategy of three-dimensional visualization technique [2 year]

      Firstly, the operation strategies based on original CT or MRI image data will be made by the team, Secondly, the operation strategies based on three dimensional reconstruction models will be made by the team, then, actually surgical strategies will be recorded. The change of operation strategy will be assessed by comparing the strategy of the 2D model and 3D model. The change rate of operation strategy will be recorded and presented as percentage.

    2. Impact on complications of three-dimensional visualization technique [2 year]

      The complications are refer to the classification of Clavien-Dindo, including postoperative bleeding, biliary fistula, ascites, postoperative liver failure, renal dysfunction, pleural effusion, abdominal cavity infection, abdominal abscess, incision infection, the occurrence cases of each complications (number) will be recorded.

    Secondary Outcome Measures

    1. Blood routine examination (the 1th, 3 th, 5th, 7th) [2 year]

      Hemoglobin(g/L), Platelet(109/L), and neutrophilic granulocyte percentage (%)

    2. Urine routines (the 1th, 3 th,5th, 7th) [2 year]

      Urine specific gravity, urine protein(mg/dl), urine sugar(mmol/L), leukocytes in urine(number/ul), urine erythrocyte(number/ul)

    3. Stool Routine (the 1th, 3 th,5th, 7th) [2 year]

      Defecate occult blood test, Microorganisms (mold, parasites, etc.)

    4. Blood biochemistry (the 1th, 3 th,5th, 7th) [2 year]

      Serum albumin(g/L), serum pre-albumin(g/L), serum globulin(g/L), total bilirubin(µmol/L), direct bilirubin(µmol/L),serum glutamic-oxaloacetic transaminase (AST, IU/L), serum glutamic pyruvic transaminase (ALT, IU/L), alkaline phosphatase (ALP, IU/L), gamma glutamyl transpeptidase(r-GGT, IU/L) ,Serum creatinine(µmol/L), Urea(mmol/L), Blood sugar(mmol/L)

    5. Tumor marker [2 year]

      Alpha fetoprotein(AFP, ng/L), Carbohydrate antigen-199(CA-199, ku/L), Carbohydrate antigen-125(CA-125, ku/L), Carcinoembryonic antigen (CEA, ng/L), Carbohydrate antigen-153(CA-153, ku/L)

    6. The blood coagulation function (the 1th, 3th, 5th, 7th) [2 year]

      prothrombin time (PT, s), partial thromboplastin time (APTT), international normalized ratio (INR), plasma prothrombin activity (PTA, %), fibrinogen (FIB, g/L), d-dimer(mg/L)

    7. Inflammatory biomarkers [2 year]

      C-reactive protein, procalcitonin

    8. Preoperative viral loading [2 year]

      HBV(hepatitis B virus)- DNA、HCV(hepatitis C virus)- RNA

    9. Postoperative results of paraffin wax and immunohistochemical index [2 year]

      CK7、CK18、CK19、Hepatocyte、CD34(vascular)、S-100(nerve)、D2-40(lymphatic)、AFP、Ki67

    10. Postoperative pathologic examination [2 year]

      The stage of TNM, The condition of resection (R0/R1/R2), the condition of liver cirrhosis, the pathological type of the tumor (Nipple type/nodule type/infiltration type)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. 18 years≤ Age ≤70 years

    2. Complying with the diagnosis criteria of hilar cholangiocarcinoma.

    3. Without intrahepatic or extrahepatic extensive cancer metastasis.

    4. Preoperative serum bilirubin ≤51.3 umol/L or preoperative serum bilirubin < 200 umol/L after the drainage by PTCD(percutaneous transhepaticcholangial drainage)/ENBD(endoscopic nasobiliary drainage).

    5. The patients are volunteered for the study.

    Exclusion Criteria:
    1. Patients with mental illness.

    2. Patients can't tolerate the operation owe to a variety of basic diseases (such as severe cardiopulmonary insufficiency, renal insufficiency, cachexia and blood system diseases, etc.)

    3. The patients refused to take part in the study.

    4. There are other co-existed malignant tumors.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Zhujiang Hospital of Southern Medical University Guangzhou Guangdong China 510282

    Sponsors and Collaborators

    • Zhujiang Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Zhujiang Hospital
    ClinicalTrials.gov Identifier:
    NCT03132649
    Other Study ID Numbers:
    • 201701
    First Posted:
    Apr 28, 2017
    Last Update Posted:
    Apr 19, 2018
    Last Verified:
    Feb 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Zhujiang Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 19, 2018